Q3 Review: Editor’s Picks Of Scrip's Top Stories
COVID-19 Product Development, Gene Therapy Setbacks And Record-Breaking IPOs
Executive Summary
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.